TP53 and non-small cell lung carcinoma: It has been shown that micromolar doses (10–50 μM) of resveratrol-treatment in non-small-cell lung cancer cells can lead to a significant increase in SA-β-Gal staining and enhanced p53 and p21 expression, suggesting that the anticancer effect of resveratrol is largely attributable to the induction of senescence [166].